Profound Medical (TSE:PRN) Trading Down 0.9%

Profound Medical Corp. (TSE:PRN) traded down 0.9% on Friday . The company traded as low as C$11.14 and last traded at C$11.14. 6,623 shares were traded during trading, a decline of 1% from the average session volume of 6,719 shares. The stock had previously closed at C$11.24.

Profound Medical Stock Performance

The firm has a market cap of C$272.71 million, a P/E ratio of -6.79 and a beta of 0.83. The company has a debt-to-equity ratio of 16.95, a quick ratio of 14.98 and a current ratio of 8.61. The stock’s 50-day moving average is C$12.90 and its 200 day moving average is C$11.76.

Profound Medical (TSE:PRN) last issued its quarterly earnings data on Thursday, August 8th. The company reported C($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of C($0.38). The business had revenue of C$3.06 million during the quarter, compared to analyst estimates of C$3.42 million. On average, research analysts predict that Profound Medical Corp. will post -1.9000001 earnings per share for the current year.

Insider Activity at Profound Medical

In other news, Senior Officer Rashed Osman Dewan bought 9,765 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were acquired at an average cost of C$12.85 per share, for a total transaction of C$125,480.25. 8.66% of the stock is owned by insiders.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.